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1. Introduction 
Almost most mental illness, such as schizophrenia, bipolar disorder, and depression are 
associated with undue medical morbidity and mortality. It represents a major health 
problem, with 20 to 30 years shorter lifetime mortality are primarily due to premature 
cardiovascular disease (myocardial infarction, stroke…). The cardiovascular events are 
strongly linked to non modifiable risk factors such as age, gender, personal and/or family 
history, but also to crucial modifiable risk factors, such as overweight and obesity, 
dyslipidemia, diabetes, hypertension and smoking. 
Although these classical risk factors exist in the general population epidemiological studies 
suggest that patients with severe mental illness have an increased prevalence of these risk 
factors. 
Another point is the causes of increased metabolic and cardiovascular risk in this population 
are related to poverty, poor diet, sedentary and compared to the general population. The 
increased morbidity and mortality limited behaviour access to medical care, but also to the 
use of psychotropic medication. Over recent years it has become apparent that antipsychotic 
drugs can have a negative impact on some of the modifiable risk factors. 
2. Epidemiological studies 
Results of most research on the physical health of people with mental health illness suggest 
the morbidity and the mortality from certain physical disease is high in these populations. 
Patients with schizophrenia are a medically vulnerable population due to underdiagnosed 
medical problems, and minimal or not utilization of primary care services. Not only there is 
increased medical morbidity among these patients, there is also increased mortality. 
Medical comorbidity in patients with bipolar disorder, is associated with an intensification 
of bipolar depressive symptoms and other indices of bipolar severity, as well as premature 
mortality. Somatic health issues remain underrecognized and suboptimally treated. 
2.1 Mortality 
An increasing number of studies have found higher rates of mortality in schizophrenia 
patients due to natural causes (Mortensen & Juel, 1993; Ruschena et al, 1998). Such increased 
rates of mortality due to natural causes highlight the failure to detect and manage physical 
health conditions in this group. In meta-analysis deaths due to natural causes accounted for 
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59% of the excess mortality in schizophrenia (Brown, 1997). Respiratory and cardiovascular 
diseases are the most common causes of natural death. The standard mortality ratio (SMR) 
for respiratory disease was 226 (95%CI, 209-244) and for cardiovascular disease 110 (95%CI, 
105-115) (Brown, 1997). However, another study found an SMR of 1.78 for men and 0.86 for 
women with schizophrenia for ischemic heart disease (Lawrence et al, 2003). Analysis of 
standardized mortality ratios for deaths from natural causes showed an increased risk of 
death in patients with a wide range of psychiatric conditions, including substance misuse, 
schizophrenia, bipolar disorder and unipolar depression. The Standardized mortality ratios 
(SMR) showed that in schizophrenia it is 1.57 for all cause mortality, and cardiovascular and 
cancer deaths accounted for the largest number of deaths with SMRs of 1.04 and 1.00 
respectively (Harris & Barraclough, 1998). Depression confers a 24% increased risk of dying 
within the next 6 years (Wulsin, 2000). A study published through the Centers for Disease 
Control and Prevention (CDC) compared the mortality of public mental health patients in 8 
states with the mortality of the states’ general population, for 1997 through 2000. In all the 
study states, mental health had a higher risk of death than the general population and died 
at much younger ages compared with their cohorts. In all states studied, cardiac disease was 
found to be the leading cause of death in mentally ill patients. And this population had lost 
decades of potential years of life, with average exceeding 25 years (Colton & Manderscheid, 
2006). 
Another indicator of the medical care is avoidable mortality. These indicators are calculated 
by selecting the number of avoidable causes of death considered amenable to health care 
(Rustein et al, 1976). A follow-up study of 30045 psychiatric in-patients born between 1912-
1970 was conducted to specifically address avoidable mortality. The standardized rate ratios 
(SRR) for male patients with schizophrenia are 3.74 (95%CI, 2.38-5.89) and 3.99 (95%CI, 2.47-
6.44) for females (Ringback Weitoft et al, 1998). 
2.2 Morbidity 
A study list some of the common physical conditions found in people with psychosis. 
These include diabetes, hyperlipidemia, cardiovascular disease, obesity, malignant 
neoplasms, HIV/AIDS, hepatitis, osteoporosis, hyperprolactinemia, irritable bowel 
syndrome and helicobacter pylori infection (Lambert et al, 2003). The prevalence of 
physical illness in medically screened chronic psychiatric samples has been variously 
reported to be 12-53% (Lyketsos et al, 2002). Another study estimate that 35% of 
psychiatric patients have undiagnosed physical disorder (Felker et al, 1996).Some studies 
have attempted to establish whether medical comorbidity exacerbates patient’ psychiatric 
condition (Bartsch et al, 1998). 
Not only do patients with mental illness die of natural causes at high rate, when medical 
conditions occur, these patients are much more likely to underdiagnosed and undertreated. 
Several studies have shown that the detection rate of physical illness among patient with 
mental illness is very poor. A study estimated that 45% of patients in California’s public 
mental-health system had physical disease and, of these, 47% were undetected by the 
treating physician (Koran, 1989). Another study of psychiatric clinic patients revealed 
remarkably similar findings: 43% of patients had physical illnesses and, of these, 48% had 
not been diagnosed by the referring doctor, non-psychiatrist physicians had missed 33% and 
psychiatrists had missed 50% (Koranyi, 1979). Hall et al found that 46% of patients admitted 
to a research ward had an unrecognized physical illness that either caused or exacerbated 
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their psychiatric illness; 80% had physical illnesses requiring treatment, and 4% had 
precancerous conditions or illnesses (Hall et al, 1981). 
Research indicates that 25% to 80% of patients with schizophrenia and other mental illness 
have a serious medical comorbidity, yet less than half of these medical conditions are 
diagnosed (Cradock-O’Leary et al, 2002). 
3. Causes of poor physical health in mental illness 
A number of reasons exist to explain the poor detection of physical health problems in 
patient with mental illness. Some patients are unaware of any physical health problems, 
usually a consequence of cognitive deficits associated with their mental illness (Goldman, 
1999). Often there is a reluctance to seek medical help and when it sought patient with 
mental health find it difficult to describe their problems to a medical practitioner, or present 
with atypical medical symptoms. Patient with schizophrenia have been shown to have a 
high tolerance for pain and subsequently are less likely to report this symptom (Dworkin, 
1994). Another complexity concerns the effects of psychiatric illness on perceived physical 
health. For example, depression can lead to an increase in perceived physical symptoms and 
worsening of subjective health outcomes. 
The management of medical conditions is a complex and problematic issue, arising largely 
because of the separation of medical and psychiatric health care services. The stigma of 
mental illness is one obvious barrier preventing psychiatric patients from receiving 
adequate physical health care, as some physicians may be uncomfortable in working with 
this patient. Another concern is managing physical conditions where patients that have an 
increased prevalence with psychiatric illness and where there is a general lack of treatment 
compliance. The challenging task of managing physical illness with this patient requires 
skill, patience and experience as patients often present late with complications. (Table 1) 
 
System-Related Barriers 
        Lack of insurance coverage 
        Lack of access to health care 
        Stigmatization by health care providers 
        Lack of understanding of benefits of preventive services by health care workers 
        Lack of integration of medical and mental health systems 
Patients–Barriers 
        Poverty 
        Non compliance 
        Pour communication skills 
        Denials of illness Related 
Table 1. Barriers to health care for patients with mental illness. Adapted from Goldman. 
3.1 Lifestyle risk factors 
In recent years, there is a growing concern about physical illness in patients with mental 
illnesses, specifically the risk of cardiovascular disease. Those patients are more likely to be 
overweight, to smoke, to have hypertension, hyperglycemia or diabetes, and dyslipidemia 
(Table 2). 
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Estimated prevalence, % (RR)
Modifiable risk factors Schizophrenia Bipolar disorder 
Overweight 45–55% (1,5–2) 21–49% (1-2) 
Smoking 50–80% (2-3) 54-68% (2-3) 
Diabetes 10-15% (2) 8-17% (1,5-2) 
Hypertension 19-58% (2-3) 35-61% (2-3) 
Dyslipidemia 25-69% (≤5) 25-38% (≤3) 
Metabolic syndrome 37-63% (2-3) 30-49% (1,5-2) 
Table 2. Estimation prevalence and relative risk 5 (RR) of modifiable cardiovascular disease 
risk factors in schizophrenia and bipolar disorder compared to the general population. 
Adapted from Correll, 2007 
3.1.1 Obesity 
Excessive body weight increases the risk of morbidity from number conditions, including 
hypertension, dyslipidemia, type II diabetes, coronary heart disease. Excess abdominal fat is 
associated with dyslipidemia, hypertension and glucose intolerance. Risk of comorbid diseases 
has been shown to rise as BMI increases above 25 kg/m2. In psychiatric practice, weight gain 
is a long recognized and commonly encountered problem. A study of patients with 
schizophrenia reported 51% of males and 59% of females to be clinically obese, compared with 
33% of people with other psychiatric disorders. This study provided an estimate of mean 
weight gain in patients who received standard doses of antipsychotics over 10-week period. 
The mean increases were 4.45 kg with clozapine, 4.15 with olanzapine, 2.92 kg with sertindole, 
2.10 kg with risperidone, and 0.04 kg with ziprasidone (Allison & Casey, 2001). It is important 
to note that substantial weight gain is associated with both atypical (eg, clozapine, olanzapine) 
and conventional (eg, thioridazine, chlorpromazine) antipsychotics. 
3.1.2 Smoking 
The prevalence of smoking greatly exceeds that in the general population (Table 1) Heavy 
cigarette smoking is intimately associated with schizophrenia and it may have implications 
for the underlying neurobiology of the disease. Smoking is a good example of how behavior 
and treatment interact to increase morbidity at a number of levels. It is a risk factor for 
respiratory and ischemic heart disease and stroke. Cigarette smoking induces hepatic 
microsomal enzymes, which increase the metabolism of psychotropic medication, reducing 
plasma levels of antipsychotics notably olanzapine and clozapine. It may influence the 
patient’s behavior and the treatment outcome. Therefore smokers usually require greater 
levels of antipsychotic medication than non-smokers to achieve similar blood levels. 
3.1.3 Diabetes 
It is another risk factor for coronary atherosclerosis that is associated with metabolic 
abnormalities that result in changes in the transport, composition and metabolism of 
lipoproteins. 
3.1.4 Hypertension 
Is a cardiovascular risk factor as it produces structural changes within the arteries. The seq 
uel of hypertension are greatly affected by comorbidities such as dyslipidemia, smoking, 
diabetes, lack of physical activity, sodium intake, and stress. 
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Other risk factors are attributable to unhealthy lifestyle, including social scale such as 
unemployment, poorer financial standing, poor diet and sedentary behaviour. 
Concerning diet, a study (Mc Creadle, 2003) examined in detail the dietary intake of 102 
people with schizophrenia in Scotland. Their fruit and vegetable consumption averaged 16 
portions per week, less than half the recommended intake. 
Brown et al, 1999 and Mc Creadle, 2003 found that patients with schizophrenia tended to 
take only small amounts of exercice. Factors such as features of the illness, sedative 
medication and lack of opportunity and general motivation may be relevant. 
3.2 Medication 
Psychotropic medication is associated with a host of physical complications and side effects. 
Old antipsychotic medication was associated with neurologic side effects, including 
involuntary movement disorders, such as akathisia, parkinsonism, tardive dyskinisia. New 
antipsychotics are more commonly use. Despite the low propensity of new antipsychotics 
towards extra pyramidal side effects other adverse effects associated with them include 
excessive weight gain, metabolic disturbances. Medical conditions attributed to the use of 
typical and atypical antipsychotic medication include diabetes, hyperlipidemia, and 
cardiovascular disease: specifically hypertension and cardiac arrhythmias, obesity (Meyer, 
2002; Davidson, 2002). 
4. The metabolic syndrome 
Much attention has been focused on the metabolic syndrome which brings together a series 
of abnormal clinical and metabolic findings which are predictive of cardiovascular risk. The 
most commonly used definition for the metabolic syndrome are the Adult Treatment Panel 
III (ATP III) of the National Cholesterol Education Program (NCEP), (Jama, 2001) and the 
adapted ATP-III-A proposed by the American to Heart Association following the American 
Diabetes Association lowering of the threshold for impaired fasting glucose 100mg/dl. 
(Quindy et al, 2005 ; Alberti et al, 2006). 
Another recent definition, by the International Diabetes Federation (Alberti et al, 2006; 
Sarafidis &, Nilsson, 2006) stressed the importance of waist circumference, using 
ethnic/race specific criteria (Table 3). 
 
 ATP III
3 out of 5 criteria 
required
ATP III A
3 out of 5 criteria 
required
IDF 
waist + 2 criteria 
required 
Waist (cm) M>102, F>88 M>102, F>88 M≥94,F≥80 
Blood pressure ≥130/85* ≥130/85* ≥130/85* 
HDL cholesterol (mg/dl) M<40, F<50 M<40,F<50 M<40,F<50 
Triglycerides (mg/dl) ≥150 ≥150 ≥150 
Fasting glucose (mg/dl) ≥110** ≥100** ≥100** 
*or treated with antihypertensive medication  
**or treated with insulin or hypoglycemic medication 
Table 3. Definitions of metabolic syndrome: The metabolic syndrome has been shown to be 
an important risk factor for the development of both type 2 diabetes and cardiovascular 
disease. 
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In the study, the clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), one 
third of patients met the NCEP criteria for metabolic syndrome at baseline (Mc Eoy et al, 
2005 ; Meyer et al, 2005). 
And from this study, 88% of patients with dyslipidemia were not receiving treatment, as 
were 62% of the hypertensive patients and 38% those with diabetes (Nasrallah et al, 2006). 
The presence of the metabolic syndrome increases the risk for the distribution of fat within 
the body is a key factor. Abdominal fat distribution, particularly visceral adiposity, increases 
the risk of dyslipidemia, glucose intolerance, and cardiovascular disease. Multiple organ 
systems are affected, including adipose, muscle, hepatic, nervous, and adrenal tissues, and 
the most important site of impact is the vasculature. The concept of insulin resistance is 
central to the metabolic syndrome. Insulin resistance is a major contributor to glucose 
intolerance, and the lipoprotein abnormalities seen in the metabolic syndrome are also 
predictable, at least in part, from the known effects of insulin to inhibit lipolysis in 
adipocytes. With resistance to insulin, unchecked lipolysis leads to increased delivery of free 
fatty acids to the liver for triglyceride synthesis and packaging into very low-density 
lipoprotein (VLDL) particles. Higher VLDL levels contribute to lower HDL levels because of 
the reciprocal exchanges between these lipoproteins mediated by cholesterol ester transfer 
protein. Is has been shown that blood pressure is related to insulin resistance independent 
of differences in age, gender, and degree of obesity(Zavaroni et al,1992). Visceral obesity is 
the primary determinant of insulin resistance and, as such, represents the fundamental 
pathophysiologic change leading to the metabolic syndrome. The risk of insulin resistance 
increases with adiposity, particularly the amount of visceral adiposity. Insulin resistance is 
associated with impaired glucose control, increase plasma triglycerides, reduced high-
density lipoprotein (HDL) cholesterol, increased blood pressure, increased risk of blood 
clotting, and increases in markers of inflammation, all which are associated with an increase 
risk for cardiovascular disease. Thus, markers of insulin resistance, such as elevated fasting 
plasma Triglycerides, can be a key point for monitoring and evaluating a patient’s risk. 
5. Effects of antipsychotics treatment 
Antipsychotic treatment is associated with metabolic side effects that include various 
degrees of weight gain, dyslipidemia and susceptibility to type 2 diabetes (Newcomer, 
2005). 
Elevated blood lipids, particularly triglycerides, are associated with some typical 
antipsychotic agents. Shortly after their introduction, phenothiazines were found to elevate 
serum triglyceride and total cholesterol levels. Then much was written on the effects of 
specific atypical drugs on lipid profiles. Both clozapine and olanzapine have been shown to 
cause significant hypertriglyceridemia compared with typicals. Studies have also reported a 
significant association between weight gain and triglyceride change for patients under 
atypical antipsychotic therapy (Meyer, 2001). 
The atypical antipsychotics vary in their propensity to induce weight gain (Table 4): 
clozapine and olanzapine produce the most weight gain, quetiapine and risperidone 
produce intermediate weight gain, and ziprasidone and aripiprazole produce the least 
weight gain (Allison et al, 1999; American Diabetes Association [ADA], 2004). The 
differences in weight gain associated with these agents reflect their order of risk for insulin 
resistance, glucoregulatory dysfunction, and dyslipidemia (Haupt & Newcomer 2002; ADA, 
2004). 
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Antipsychotic Weight Risk for diabetes Worsening lipid 
proli B 
Clozapine +++ + + 
Olanzapine +++ + + 
Risperidone ++ D D 
Quetiapine ++ D D 
Ziprasidone +/- - - 
Aripiprazole +/- - - 
aAdapted with the permission from the American Diabetes Association Abbreviation:  
D = discrepant results  
Symbols: + = increased effect, - = no effect 
Table 4. Atypical antipsychotic drugs and metabolic disturbancesa 
Metabolic disturbances related to atypical antipsychotics may result from a direct alteration 
of insulin sensitivity and/or insulin secretion. Antipsychotic affinity at both histamine and 
muscarinie acetylcholine receptors correlates with weight gain and metabolic liability 
(Matsui-Sakata, 2005) and impaired parasympathic regulation of β all activity may 
contribute to metabolic risk (Silvestre &-Prous, 2005). Certain antipsychotic agents may 
directly impair glucose transporter function. Direct attenuation of glucose transporter 
function by antipsychotic agents would result in elevations in circulating glucose and a 
compensatory hypersecretion of insulin, which overtime may further reduce insulin 
sensitivity, triggering the cascade of events leading to metabolic syndrome and type 2 
diabetes (Dwyer & Donohoe, 2003). 
Some antipsychotic drugs increase appetite and this leads to adiposity. Affinity of the 
antipsychotic drugs for histamine-1 (H1) receptors closely correlates with weight-gaining 
potential and appears to involve H1 receptor-linked activation of hypothalamic AMP-
kinase. Also, 5-HT2C receptor antagonism may contribute to weight gain. The H1 and 
5HT2C blocking effects of antipsychotic medications may interfere with leptin-mediated 
appetite suppression (Reynolds,2006; Matsui-Sakata et al,2005). 
Adiposity alone does not explain the potential side effects of atypical antipsychotic 
medications. Animal and human studies describe the adverse effect of clozapine and 
olanzapine on insulin and glucose metabolism (Hasnain & Vieweg, 2008). Significant insulin 
resistance has also been documented in non-obese patients receiving clozapine or 
olanzapine versus those receiving risperidone (Henderson et al, 2006). Diminished or 
inefficient insulin release from pancreatic beta cells as well peripheral insulin resistance may 
underlie the diabetogenic effect of some antipsychotic medications. Blocking muscarinic 
type 3 and 5-HT1A receptors may be a factor to diminished pancreatic beta-cells 
responsiveness and blocking 5HT2A receptor may suppress glucose uptake in muscle 
(Nasrallah, 2008). Some antipsychotic medications may impair and/or alter the action of 
insulin on adipocytes leading to progressive lipid accumulation (Vestri et al, 2007). The 
impaired effect of insulin on adipocytes may explain weight gain independent dyslipidemia 
(De leon et al, 2007, Birkenaes et al, 2008). 
Another study examine whether patients taking selective serotonin reuptake inhibitors 
(SSRIs) are more likely to have elements of the metabolic syndrome compared with those 
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taking no psychotropic drugs. Patients taking SSRIs had a significantly increased prevalence 
of obesity, abdominal fat, and hypercholesterolemia. The associations with this factors were 
significant after adjustment for age, gender , and several covariates. The individuals SSRIs 
might display differences in their side effect profile, the study performed analysis of the 
various SSRIs. Paroxetine was strongly associated with general and abdominal obesity but 
not with hypercholesterolemia, whereas citalopram was associated with neither obesity nor 
dyslipidemia. Patients taking sertraline, fluoxetine, or fluvoxamine, SSRIs treatment was 
significantly associated with abdominal obesity and with hypercholesterolemia. SSRIs 
induce transcriptional activation of cholesterol and fatty acid biosynthesis. The lipogenic 
effect could represent a common mechanism for explaining in part the lipid disturbances 
(Reader et al, 2006). 
Weight gain is a major side effect of the main mood stabilizers. Chronic treatment with 
lithium is associated with increased weight, reaching more than 10kg in 20% of patients 
(Garland et al, 1998).Valproic acid leads to unequivocal weight gain. Lamotrigene, another 
anticonvulsant that acts as a mood stabilizer, is not associated with significant weight gain 
(Zimmermann et al, 2003). 
With regard to mood stabilizers, additional factors could be involved. An insulin-like action 
cause by lithium at the treatment stage could increase fat deposition. In addition, edema 
secondary to sodium retention and subclinical hypothyroidism also contribute to weight 
gain (Garland et al, 1998). The mechanism by which the valproic acid causes weight gain is 
still little explored; an action in the sense of inhibiting oxidation of fatty acids might be 
involved (Isojärvi et al, 1998). 
Studies are not in accordance. A controlled study, with children undergoing anticonvulsant 
treatment, did not find significant changes in HDL and triglycerides levels associated with 
use of carbamazepine or valproic acid. But, in the group taking carbamazepine, there were 
was significant increase in total cholesterol levels (Fanzoni et al, 1992). 
Another study assessed 101 patients undergoing anticonvulsant therapy for at least 3 
months. Compared with controls paired for gender and age, patients taking valproic acid 
presented significantly lower total cholesterol and LDL levels; patients taking 
carbamazepine presented significantly increased HDL and apolipoprotein A levels 
(Calandre et al, 1991). 
6. Screening and monitoring  
Identification of treatable pathology in a high-risk population, that is, screening for diabetes, 
dyslipidemia, hypertension is important and facilitates preventive strategies and early 
diagnosis. Another goal is to track metabolic disturbance in relation to antipsychotic treatment. 
Dyslipidemia is a general term that defines an increase in the serum concentration of various 
lipoproteins. Lipoproteins are usually classified into three major categories: 
- Low-density lipoproteins (LDLs) are cholesterol-rich particles whose concentration is 
directly correlated with the risk of myocardial infarction and death. 
- Very-low-density lipoproteins (VLDLs) are triglyceride-rich particles whose 
concentration is strongly correlated with the level of insulin resistance and inversely 
proportional to the serum concentration of high-density lipoproteins (HDLs). 
- HDL particles are antiatherogenic lipid particles, and high serum levels of HDL are 
protective against coronary artery disease.  
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6.1 Screening 
In the general population, lipid screening with a fasting lipid profile (total chol, LDL, HDL 
and triglyceride) is recommended for all adults aged 20 years and older, repeteated every 5 
years in asymptomatic individuals (Expert Panel on Detection, Evaluation and Treatment, of 
High Blood Cholesterol in Adults, 2001). Adequate fasting, about 10 to 12 hours is necessary 
to obtain valid LDL and triglyceride levels-Target LDL levels are determined by a 
Framingham assessment based on age, sex, chol, HDL, systolic blood pressure, and smoking 
status (Wilson et al, 1998). Patients on antipsychotic treatment frequently have a metabolic 
dyslipidemia with elevations of triglyceride and reduced HDL (Cohn et al, 2004), along with 
associated features of the metabolic syndrome. Some SSRIs induced metabolic disturbance 
particularly hypercholesterolemia. 
Treatment of metabolic dyslipidemia is a secondary goal for intervention following 
achievement of LDL targets. Clinical trials show that LDL-lowering therapy reduces risk for 
coronary heart disease (CHD). For these reasons, ATP III continues to identify elevated LDL 
cholesterol as the primary goal of cholesterol-lowering therapy. Those with diabetes or 
established cardiovascular disease are considered high risk and are treated to the most 
stringent LDL targets. Risk determinants in addition to LDL cholesterol include the presence 
or absence of CHD, other clinical forms of atherosclerotic disease , and the major risk factors 
other than LDL. Other major risk factors are cigarette smoking, hypertension, low HDL 
cholesterol, family history of premature CHD, diabetes and age. These major risks are 
commonly observed in patients with mental illness.  
A variety of medical conditions and drugs can exacerbate hyperlipidemias. Elevations of the 
serum LDL cholesterol level can occur in response to hypothyroidism and nephrotic 
syndrome. Hypertriglyceridemia and decreased HDL levels are commonly seen with insulin 
resistance, diabetes, and the metabolic syndrome. This fact is usually seen in patients with 
mental illness. Individuals are characterized by their coronary risk profile according to the 
National Cholesterol Education Program Adult Treatment Panel III guidelines, as shown in 
Table 5. 
 
Lipoprotein and serum concentration Status 
Low-density lipoprotein (LDL) cholesterol) 
(primary target of therapy) 
<100 mg/dl 
100-129mg/dl 
130-159 mg/dl 
≥160 mg/dl 
 
 
Optimal 
Near optimal 
Borderline high 
High 
Total cholesterol 
<200 mg/dl 
200-239 mg/dl 
≥ 240 mg/dl 
 
Desired 
Borderline high 
High 
HDL cholesterol 
<40 
≥60 
 
Low 
High 
Table 5. ATP III Classification of LDL, Total, and HDL Cholesterol (mg/dL) 
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6.2 Monitoring 
To monitor for antipsychotic – associated metabolic disturbances, patients should be 
assessed before antipsychotic treatment is initiated. The results of such an assessment can 
also influence antipsychotic choice, particularly when patients have existing metabolic 
pathology or elevated risk factors. The frequency of subsequent assessments is different  
as it is reflected in the various antipsychotic monitoring guidelines: Mount Sinai  
(Chobarian et al, 2003), Australia (Lambert et al, 2004) ADA-APA(ADA,2004) Belgium (De 
Nayer, 2005), United Kingdom (Expert Consensus Meeting, 2004), Canada (Canadian 
Diabetes Association, 2005), France (Saravane et al, 2009) (Table 6).To summarize these 
recommendations, there are many aeras of general agreement about the importance of 
baseline monitoring before starting treatment and that patients should be followed more 
closely for the first 3 to 4 months of treatment, with subsequent ongoing reevaluation. The 
utility of the following tests and measures was emphasized: fasting plasma glucose, fasting 
lipid profile, weight and height, waist circumference, and blood pressure.  
A recent study characterizes associations between the combined warnings and 
recommendations and baseline metabolic testing and Second-Generation Antipsychotic 
Drugs (SGA). A total of 109451 patients receiving Medicaid who began taking SGA was 
compared to a control cohort of 203527 patients who began taking albuterol but did nor 
receive antipsychotic medication. The main outcome measures was the monthly rates of 
baseline serum glucose and lipid testing for SGA-treated and propensity-matched 
albuterol-treated patients and monthly share of new prescriptions for each SGA drug. In a 
Medicaid-receiving patients, baseline glucose and lipid testing for SGA was infrequent 
and showed little change following the monitoring recommendations. Initial testing rates 
for SGA-treated patients were low: glucose, 27%; lipids, 10%. The warning was not 
associated with an increase in glucose testing among SGA-treated patients and was 
associated with only a marginal increase in lipid testing rates: 1.7%; P=. 02.(Morrato, 
2010). 
The important question is given the risks in patients with mental illness, how should they be 
monitored and how should they be treated? 
Current studies indicate that patients with mental illness do not receive adequate evaluation 
and effective treatment of their cardio-metabolic problems. Effective communication 
between the primary care physician and the psychiatrist is very important for the mentally 
ill because of their impaired capacity to care for themselves. Such communication will 
improve monitoring, help early detection of metabolic disorders, and limit duplication of 
clinical or laboratory workup. Monitoring for metabolic side effects is primarily the 
responsibility of the physician prescribing antipsychotic medication and in most cases that 
would be a psychiatrist. 
If the primary care physician observes that the patient is being prescribed such drugs 
without being monitored effectively, he/she should discuss this with the psychiatrist. The 
psychiatrist may not have the expertise to manage any abnormalities that are detected and 
in such situations the primary care physician will most likely take over both monitoring and 
management. Liaison should extend to any healthcare professionals involved in the care of 
patients with mental illness.  
Given the serious health risks, patients taking antipsychotic drugs should receive 
appropriate baseline screening and ongoing monitoring. 
www.intechopen.com
 
Dyslipidemia and Mental Illness 
 
359 
 Mount 
Sinaï 
Australia ADA-
APA 
Belgium UK Canada France 
 Patients to monitor 
 Schizo-
phrenia 
any 
antipsy-
chotic 
All patients 
any 
antipsy-
chotic 
All 
patients 
SGA 
Schizo-
phrenia
SGA 
Schizo-
phrenia 
any 
antipsy-
chotic 
Schizo-
phrenia
 
All patients 
any 
antipsychotic 
Fasting 
Plasma 
Glucose 
(FPG) 
x x x x x x x 
Random 
glucose 
 x   x   
Hba1c If FPG not 
feasible 
   x   
OGTT      Follow 
up 
 
Lipids x x x x  x x 
Weight x x x x  x x 
Height x x x x  x x 
Waist 
circumfe-
rence 
x x x x  x x 
Hip  x     x 
Family 
and 
medical 
history 
x x x x  x x 
Ethnicity x x  x    
Tobacco    x    
Diet 
activity 
 x  x  x  
Signs and 
symptoms 
of diabetes 
x  x x x x x 
ECG       x 
Blood 
pressure 
 x x x  x x 
Table 6. Recommended guidelines to monitor and initial workup. 
6.2.1 Baseline monitoring 
The recommendations are that baseline screening measures be obtained before or as soon as 
clinically feasible after, the initiation of any antipsychotic medication. We have to consider 
ethnicity, dietary habits, physical activity, support system, smoking, and alcohol and drug 
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abuse. Keep in mind that psychotropic medications other than antipsychotic drugs such as 
some antidepressants and mood stabilizers may link to weight gain. The baseline 
assessments include: 
- Personal and family history of obesity, diabetes, dyslipidemia, hypertension or 
cardiovascular disease 
- Weight and height, so that BMI can be calculated 
- Waist circumference at the level of the umbilicus 
- Blood pressure 
- Fasting plasma glucose 
- Fasting lipid profile 
If any abnormalities are identified, first, patients should be informed of their condition and 
supported in making lifestyle changes to adopt a healthier diet and increase physical 
activity. Psychiatrists should not hesitate to refer the patient to the appropriate health care 
professional or specialist knowledgeable about these disorders. 
Even for patients free of metabolic disorders, monitor potential risk factors. Weight gain 
may not be dose-dependent and patients with low body mass index at baseline may be 
particularly vulnerable to weight gain. Glucose and lipid metabolism abnormalities may 
occur without weight gain.  
6.2.2 Follow-up monitoring 
The patient’s weight should be reassessed at 4, 8, and 12 weeks after initiating or changing 
SGA therapy and quarterly thereafter at the time of routine visits. If a patient gains > 5% of 
his or her initial weight at any time during therapy, one should consider switching the 
medication. When switching, consideration should be given to all aspects of the individual’s 
condition, the comparative risks and benefits of changing medications, and the individual’s 
response to medication in managing the primary symptoms of the mental illness. In some 
cases, cost and availability may also be a consideration. 
Fasting plasma glucose, lipid profile, and blood pressure should also be assessed 3 months 
after initiation of medication. Thereafter, blood pressure, plasma glucose values, lipid 
profile should be obtained annually or more frequently in those who have a higher baseline 
risk for the development of diabetes, dyslipidemia or hypertension. 
7. Treatment 
With all the risk factors and in the case of dyslipidemia and to reduce the global mortality of 
patients with mental illness we should consider lipid goal of therapy for these patients. The 
benefits and risks of different therapeutic agents used in the treatment of dyslipidemia  and 
its comorbidities should be considered in the context of the patient’s psychiatric condition 
and treatment. 
7.1 Drugs 
ATP III recommends a multifaceted lifestyle approach to reduce risk for coronary heart 
disease (CHD). This approach is designated therapeutic lifestyle changes (TLC). Some 
patients whose short-term or long-term risk for CHD is high will require LDL-lowering 
drugs in addition to TLC. When drugs are prescribed, attention to TLC should always be 
maintained and reinforced. Available drugs are: 
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- HMG-CoA reductase inhibitors: statins, their side effects are myopathy and increased 
liver enzymes 
- Bile acid sequestrants , their side effects including gastrointestinal distress, constipation 
and decreased absorption of some drugs 
- Nicotinic acid side effects are essentially flushing, hyperglycemia, hyperuricemia 
(gout), upper gastrointestinal distress and hepatotoxicity 
- Fibric acids, with their side effects including dyspepsia, gallstones, myopathy, 
unexplained non-CHD deaths in WHO study 
All these drugs reduced major coronary events, CHD deaths but we have to be carefull with 
their side effects and contraindications when prescribing these drugs. 
Beyond the underlying risk factor, therapies directed against the lipid and nonlipid risk 
factors of the metabolic syndrome will reduce CHD risk. 
The management of dyslipidemia in mental health is defined, as recommended by the 
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes by: 
The lifestyle interventions with diet, increased physical activity and smoking cessation. 
They are the firs-line treatments to decrease the risk for cardiovascular disease in patient 
with metabolic syndrome. 
7.2 Diet 
Interventions that address nutrition and weight management should become a routine part 
of psychiatric care. Patients with mental illness did not know the components of a healthy 
diet. The healthy eating behavior includes: 
- Cutting down fast food 
- Increased healthy food items like fruits, vegetables, fish and decreased high glycemic 
index food items and monounsaturated fats 
- Decreased processed fat free food 
- Consume 4-6, but small meals 
- Minimizing intake of soft drinks with sugar and with artificial sweetener 
The lifestyle changes should be gradual and adapted individually for each patient. There are 
various educational and psychosocial programs that address the issues of health and 
wellness exist, like ‘ The Healthy Living’ program (Vreeland, 2007; Hoffmann et al, 2006). 
7.3 Physical activity 
Patients who developed psychosis are more likely to be physically inactive (OR=3.3,95%  
CI 1.4-7.9) and to have poor cardio respiratory fitness (OR=2.2, 95% CI 0.6-7.8) compared 
with those who did not develop psychosis (Koivukangas et al, 2010). Modern guidelines on 
managing the physical health risks associated with schizophrenia include a 
recommendation about the importance of physical activity levels and fitness. This 
recommendation includes: 
- To advise patients to engage at least 30 minutes of moderately vigorous activity on 
most days of the week 
- Reduce sedentary behaviors such as TV watching, video/computer games 
- Treating/reducing sedation and extra pyramidal effects of medications  
Some studies showed that physical activity, with and without diet, resulted in modest 
weight loss, reduction of blood pressure and decreases in fasting plasma concentrations of 
glucose and insulin (Vancampfort et al, 2009). 
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7.4 Medication 
In the general population there are many studies evaluating the impact of lipid lowering in 
primary and secondary prevention of coronary heart disease and stroke, but there are some 
concerns about its value in primary prevention, especially in vulnerable population (Vrecer 
et al, 2003). 
Whether a low or lowered serum cholesterol level is associated with harm has been the 
subject of debate for a long time; ever since the unexpected finding of an increased risk of 
noncardiovascular mortality in early trials of lipid-lowering therapy. Subsequent research 
has generated conflicting evidence regarding the relation between cholesterol and violent 
behavior, mental illness , with positive studies imputing alterations in central serotoninergic 
activity as a potential underlying mechanism. A case-control study studied a cohort of 94441 
individuals, 458 had newly diagnosed depression and 105 had a recorded diagnosis of 
suicide risk. Compared with matched control subjects, and even after adjustment for 
potential confounders, neither dyslipidemia nor its treatment was associated with an 
increase risk of depression. Similarly, no association was found between treatment and 
suicide risk. (Yang, 2003).  
A 3-month study demonstrated that statins prescribed to patients with schizophrenia  
and severe dyslipidemia whilst taking antipsychotic medication led to a significant 
improvement in lipid profiles (Hanssens et, 2007). An earlier study with rosuvastatin 
proved effective in managing dyslipidemia in schizophrenic patients on antipsychotics. This 
study showed improvement in lipid profiles but not benefits in terms of high-density 
lipoprotein, waist measurement, BMI or glucose homeostasis (De Hert et al, 2006). 
This last study supports the view that statins can be safely used in the short term to control 
abnormal lipids levels. However, there are no long-term data on its impact on either relapse 
or all-cause mortality, and again this is a priority for research. 
The presence of metabolic syndrome is an indication for more aggressive lipid-lowering 
measures. Medications that raise HDL, nicotinic acid or fibrates, may be particularly 
beneficial in patients with metabolic syndrome, but they have not been as widely studied as 
medications that lower LDL-cholesterol in patients with mental illness. 
The preferred initial management is still very much a lifestyle modification approach 
including exercise and diet.  
8. Conclusion 
Despite the availability of published clinical guidelines, patients with mental illness 
receiving medications remain vulnerable to the cardio-metabolic complications of these 
drugs. Implementation of a coordinated metabolic monitoring and management program 
for patient with mental illness will require a review of current practice and the introduction 
of new procedures, both of which will require time and effort on the part of the health care 
community. 
Involvement of patient with mental illness in their treatment program will require the 
provision of information about their condition and medication and the development of 
approaches that empower, encourage, and support patients in their decisions on treatment 
and well-being. 
The evaluation of new therapies should include detailed assessments of physical health and 
future risk estimates in addition to standard psychiatric outcomes. Psychiatrists have to 
arrange the appropriate examination and investigation of patients at risk of developing 
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significant physical morbidity, working very closely with general practitioners and with 
other specialists when appropriate. We have to weight up the risk of metabolic disturbance 
and its potential impact on future cardiovascular risk when selecting an antipsychotic drug. 
We have to take a careful medical history and be prepared to monitor weight and other 
metabolic risk, such as glucose and lipid profile. The lipid area is significantly understudied 
in patients taking antipsychotic medications. Lipids may be more important than diabetes 
because dyslipidemia appears to occur at a higher prevalence in this patient population. 
Lipid levels are a significant problem because physicians are seeing hypertriglyceridemia. 
Knowing what we know about what causes and contributes to cardiovascular disease, we 
are obliged to play detective and figure out why psychiatric patients are dying sooner and 
more often of cardiovascular disease than the general population. 
The big challenge for all is to ensure that the physical health of patients with mental illness 
is given the priority it deserves, helping them to face their future with the lowest possible 
morbidity and mortality odds stacked against them. 
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